|
SK55593A3
(en)
|
1991-03-05 |
1993-10-06 |
Wellcome Found |
Expresion of recombinant proteins in attenuated bacteria
|
|
DK0897983T3
(da)
|
1991-10-25 |
2003-08-11 |
Immunex Corp |
Antistoffer mod CD40-L
|
|
US5962406A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
EP0659086B1
(en)
|
1992-09-04 |
1998-11-11 |
The University of Saskatchewan |
Novel bacterial vaccines using vaccine strains of pathogenic bacteria
|
|
AU1059095A
(en)
|
1993-11-24 |
1995-06-13 |
Australian National University, The |
Treatment of viral disease with cd40l peptide
|
|
PT812206E
(pt)
|
1995-03-01 |
2002-11-29 |
Immunex Corp |
Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
|
|
NZ311335A
(en)
|
1995-06-07 |
1998-05-27 |
Immunex Corp |
Cd40l muteins and their use as ligands
|
|
US6479258B1
(en)
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6306387B1
(en)
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
EP1059932A1
(en)
|
1997-12-19 |
2000-12-20 |
Immunex Corporation |
Method for reducing susceptibility to hiv infection
|
|
GB9806449D0
(en)
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
IT1299583B1
(it)
|
1998-05-19 |
2000-03-16 |
Vander Way Limited |
Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
|
|
ATE403728T1
(de)
|
1998-09-04 |
2008-08-15 |
Emergent Product Dev Uk Ltd |
Attenuierte salmonella spi2 mutante als antigen- träger
|
|
US7300774B1
(en)
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
IL144952A0
(en)
|
1999-04-16 |
2002-06-30 |
Hoffmann La Roche |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
US7118751B1
(en)
|
1999-10-14 |
2006-10-10 |
Trubion Pharmaceuticals, Inc. |
DNA vaccines encoding antigen linked to a domain that binds CD40
|
|
DK1112747T3
(da)
|
1999-12-28 |
2004-10-25 |
Akzo Nobel Nv |
Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
|
|
EP1255560B1
(en)
|
2000-02-02 |
2008-10-29 |
UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE |
Cd40 ligand adjuvant for respiratory syncytial virus vaccine
|
|
BR0109322A
(pt)
|
2000-03-17 |
2002-12-10 |
Upjohn Co |
Materiais e métodos de vacina de salmonella
|
|
GB0015426D0
(en)
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
WO2002000232A2
(en)
*
|
2000-06-26 |
2002-01-03 |
Maxygen, Inc. |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
AU2002221780A1
(en)
|
2000-10-31 |
2002-05-15 |
F.Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
US7220723B2
(en)
|
2001-05-15 |
2007-05-22 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
BR0209689A
(pt)
|
2001-05-15 |
2006-02-07 |
Long Island Jewish Res Inst |
Uso de fragmento de hmg como agente anti-inflamatório
|
|
ATE438710T1
(de)
|
2001-05-15 |
2009-08-15 |
Ortho Mcneil Janssen Pharm |
Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
ATE395602T1
(de)
|
2001-12-19 |
2008-05-15 |
Alcedo Biotech Gmbh |
Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
|
|
US6923958B2
(en)
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
EP2380440B1
(en)
|
2002-04-15 |
2016-03-09 |
Washington University |
Regulated attenuation of live vaccines to enhance cross protective immunogenicity
|
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
JP2006510619A
(ja)
|
2002-11-20 |
2006-03-30 |
クリティカル セラピューティクス，インコーポレイテッド |
抗炎症剤としてのｈｍｇｂ断片の使用
|
|
US20040141948A1
(en)
|
2002-11-20 |
2004-07-22 |
Critical Therapeutics, Inc. |
Use of HMGB fragments as anti-inflammatory agents
|
|
WO2004046338A2
(en)
|
2002-11-20 |
2004-06-03 |
North Shore-Long Island Jewish Research Institute |
Use of hmgb polypeptides for increasing immune responses
|
|
US20040156851A1
(en)
|
2002-11-20 |
2004-08-12 |
Critical Therapeutics, Inc. |
HMGB1 combination therapies
|
|
US20050181994A1
(en)
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US20060014248A1
(en)
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US7696169B2
(en)
|
2003-06-06 |
2010-04-13 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
WO2005025604A2
(en)
|
2003-09-10 |
2005-03-24 |
The General Hospital Corporation |
Use of hmgb and hmgb fragments to decrease specific immune response
|
|
EP1673389A2
(en)
|
2003-10-10 |
2006-06-28 |
Xencor Inc. |
Novel variants of cd40l protein
|
|
CA2548347A1
(en)
|
2003-12-11 |
2005-06-30 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
US8828957B2
(en)
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
EP1740604A2
(en)
|
2004-04-27 |
2007-01-10 |
Intercell AG |
Td antigens
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
US20080305120A1
(en)
*
|
2004-06-17 |
2008-12-11 |
Medimmune, Inc. |
Immunogenic Compositions Comprising Hmgb 1 Polypeptides
|
|
WO2006012373A2
(en)
|
2004-07-20 |
2006-02-02 |
Critical Therapeutics, Inc. |
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
US8513008B2
(en)
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
DE602005025005D1
(de)
|
2004-10-07 |
2011-01-05 |
Argos Therapeutics Inc |
Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
|
|
GB0423681D0
(en)
|
2004-10-26 |
2004-11-24 |
Sec Dep For Environment Food & |
Vaccine and nucleic acids
|
|
NZ556004A
(en)
|
2004-12-21 |
2010-05-28 |
Vaxinnate Corp |
Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
US20060286074A1
(en)
|
2005-05-31 |
2006-12-21 |
Yucheng Tang |
Methods for immunotherapy of cancer
|
|
WO2007011606A2
(en)
|
2005-07-18 |
2007-01-25 |
Critical Therapeutics, Inc. |
USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
|
|
PT1949913E
(pt)
|
2005-10-07 |
2010-08-24 |
Proyecto Biomedicina Cima Sl |
Associação imunoestimuladora para a profilaxia e o tratamento da hepatite c
|
|
AU2006311752A1
(en)
|
2005-11-07 |
2007-05-18 |
Sidney Kimmel Cancer Center |
CD40 ligand fusion protein vaccine
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
WO2007130725A2
(en)
*
|
2006-02-06 |
2007-11-15 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of hmgb1 for protection against ischemia reperfusion injury
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
WO2007106073A2
(en)
|
2006-03-02 |
2007-09-20 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
EP2044198A4
(en)
*
|
2006-07-27 |
2010-09-08 |
Ligocyte Pharmaceuticals Inc |
CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
|
|
US8564612B2
(en)
*
|
2006-08-04 |
2013-10-22 |
Apple Inc. |
Deep pixel pipeline
|
|
CA2659267C
(en)
*
|
2006-08-09 |
2016-12-13 |
Medimmune, Llc |
Influenza hemagglutinin and neuraminidase variants
|
|
EP2517723B1
(en)
*
|
2006-09-18 |
2019-11-06 |
The Board of Trustees of The University of Arkansas |
Compositions and methods of enhancing immune responses
|
|
US20100292309A1
(en)
|
2007-03-08 |
2010-11-18 |
Mayo Foundation For Medical Education And Research |
Inducing immune-mediated tumor cell death
|
|
AU2008275513A1
(en)
*
|
2007-05-02 |
2009-01-15 |
Emory University |
Enhancement of glycoprotein incorporation into virus-like particles
|
|
BRPI0818736A2
(pt)
|
2007-10-30 |
2017-06-13 |
Univ Arkansas |
composições e métodos para intensificar imunorrepostas à bactéria flagelada
|
|
WO2009059298A2
(en)
|
2007-11-01 |
2009-05-07 |
Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancinc immune responses to eimeria
|
|
CN102811734B
(zh)
|
2010-01-21 |
2016-02-10 |
阿肯色大学评议会 |
增强免疫应答的疫苗载体和方法
|
|
WO2013071298A1
(en)
|
2011-11-11 |
2013-05-16 |
Nutrition Physiology Company, Llc |
Lactic acid bacteria and their use as dietary supplementals for poultry
|
|
CA2800830C
(en)
|
2010-06-09 |
2020-09-08 |
The Board Of Trustees Of The University Of Arkansas |
Vaccine and methods to reduce campylobacter infection
|